Federal Register / Vol. 88, No. 184 / Monday, September 25, 2023 / Notices 65707 

• 10 U.S.C. 1034, made applicable to 

the Public Health Service 

Commissioned Corps through section 

1129 of the Food and Drug 

Administration Safety and Innovation 

Act, Public Law 112–144, and 

implemented by Commissioned Corps 

Directive (CCD) 121.06: https://

dcp.psc.gov/ccmis/ccis/documents/ 

CCD121_06.pdf 

Other Related Policies 

• NIH Data Management and Sharing 

Policy: https://sharing.nih.gov/datamanagement-and-sharing-policy 

• Public Law 115–435—Foundations for 

Evidence-Based Policymaking Act 

(‘‘Evidence Act’’): https://

www.congress.gov/115/plaws/ 

publ435/PLAW-115publ435.pdf 

• Public Law 107–174—Notification 

and Federal Employee 

Antidiscrimination and Retaliation 

Act (‘‘No FEAR Act’’): https://

uscode.house.gov/statutes/pl/107/ 

174.pdf 

• U.S. Government Policy for 

Institutional Oversight of Life 

Sciences Dual Use Research of 

Concern: https://www.phe.gov/s3/ 

dualuse/documents/durc-policy.pdf 

• U.S. Government Policy for Oversight 

of Life Sciences Dual Use Research of 

Concern: https://www.phe.gov/s3/ 

dualuse/Documents/us-policy-durc032812.pdf 

• Public Law 92–463—The Federal 

Advisory Committee Act: https://

uscode.house.gov/statutes/pl/92/ 

463.pdf 

• Public Law 104–13—Paperwork 

Reduction Act: https://

www.congress.gov/104/plaws/publ13/ 

PLAW-104publ13.pdf 

Authorities 

Pursuant to the 2021 Presidential 

Memorandum on Restoring Trust in 

Government Through Scientific 

Integrity and Evidence-Based 

Policymaking at https://

www.whitehouse.gov/briefing-room/ 

presidential-actions/2021/01/27/ 

memorandum-on-restoring-trust-ingovernment-through-scientific-integrityand-evidence-based-policymaking/, and 

consistent with the 2009 Presidential 

Memorandum on Scientific Integrity at 

https://obamawhitehouse.archives.gov/ 

the-press-office/memorandum-headsexecutive-departments-and-agencies-3- 

9-09 and the 2010 Memorandum from 

the White House Office of Science and 

Technology Policy on Scientific 

Integrity at https://

obamawhitehouse.archives.gov/sites/ 

default/files/microsites/ostp/scientificintegrity-memo-12172010.pdf, all 

Federal agencies must establish a 

scientific integrity policy. The 

requirements of this policy are derived 

from the 2022 National Science and 

Technology Council (NSTC) Report of 

the Scientific Integrity Fast Track 

Action Committee, Protecting the 

Integrity of Government Science at 

https://www.whitehouse.gov/wpcontent/uploads/2022/01/01-22- 

Protecting_the_Integrity_of_

Government_Science.pdf, and align 

with the principles set forth in the 

NSTC guidance document A Framework 

for Federal Scientific Integrity Policy 

and Practice at https://

www.whitehouse.gov/wp-content/ 

uploads/2023/01/01-2023-Frameworkfor-Federal-Scientific-Integrity-Policyand-Practice.pdf. 

This policy is established in 

accordance with: 

1. Public Law 111–358—The America 

COMPETES Reauthorization Act of 

2010, section 103, as amended 

2. Public Law 115–435—The 

Foundations for Evidence-based 

Policymaking Act of 2018 

3. Public Law 106–554—The 

Information Quality Act of 2000 

4. 67 FR 8451—OMB Guidelines for 

Ensuring and Maximizing the 

Quality, Objectivity, Utility, and 

Integrity of Information 

Disseminated by Federal Agencies 

5. 70 FR 2664—OMB Final Information 

Quality Bulletin for Peer Review 

6. 65 FR 76260–76264—Federal Policy 

on Research Misconduct 

7. Public Law 101–12—The 

Whistleblower Protection Act 

(WPA) of 1989, as amended 

8. 41 U.S.C. 4712—The National 

Defense Authorization Act, 

Enhancement of contractor 

protection from reprisal for 

disclosure of certain information 

9. 5 U.S.C. 13103 et seq.—The Ethics in 

Government Act of 1978, as 

amended, and 5 CFR parts 2634 and 

2635, Executive Branch Financial 

Disclosure, Qualified Trusts, and 

Certificates of Divestiture and 

Standards of Ethical Conduct for 

Employees of the Executive Branch. 

10. 18 U.S.C. 201–209—Statutes 

regarding Bribery, Graft and 

Conflicts of Interest 

11. 5 CFR parts 5501 and 5502— 

Supplemental Standards of Ethical 

Conduct for Employees of the 

Department of Health and Human 

Services 

12. 5 U.S.C. Ch. 10—The Federal 

Advisory Committee Act of 1972 

13. 45 CFR part 73, Standards of 

Conduct 

14. 5 CFR part 735, Employee 

Responsibilities and Conduct 

15. HHS Protection of Human Subjects 

Regulation (45 CFR part 46). 

16. PPD 19—Protecting Whistleblowers 

with Access to Classified 

Information, 2012 

17. M–20–12—OMB Phase 4 

Implementation of the Foundations 

for Evidence-Based Policymaking 

Act of 2018: Program Evaluation 

Standards and Practices 

18. 42 CFR part 93—Public Health 

Service Policies on Research 

Misconduct 

19. 10 U.S.C. 1034, made applicable to 

the Public Health Service 

Commissioned Corps through 

section 1129 of the Food and Drug 

Administration Safety and 

Innovation Act, Public Law 112– 

144, and implemented by 

Commissioned Corps Directive 

(CCD) 121.06 

20. Health Extenders, Improving Access 

to Medicare, Medicaid, and CHIP, 

and Strengthening Public Health 

Act of 2022, Public Law 117–328, 

Division FF, title II, section 2321 

(Jan 3, 2023) 

21. Chips and Science Act, Public Law 

117–167, title VI, subtitle D, section 

10631 (Aug 9, 2022) 

Dated: September 19, 2023. 

Tara A. Schwetz, 

Acting Principal Deputy Director, National 

Institutes of Health. 

[FR Doc. 2023–20733 Filed 9–22–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Microbiology, 

Infectious Diseases and AIDS Initial Review 

Group; Microbiology and Infectious Diseases 


ddrumheller on DSK120RN23PROD with NOTICES1
65708 Federal Register / Vol. 88, No. 184 / Monday, September 25, 2023 / Notices 

1As a result of the SARS–CoV–2 (COVID–19) 

pandemic, Laboratories and Scientific Services 

implemented a one-time quadrennial timeframe for 

reoccurring audits originally scheduled to take 

place in 2020, 2021, and 2022. This postponed the 

scheduled deadline for audits and the payment of 

reaccreditation or reapproval fees by one year, after 

which audits will return to a triennial schedule. See 

19 U.S.C. 1499; Presidential Proclamation 9994, 85 

FR 15337 (March 13, 2020); Executive Order 13924, 

85 FR 31353 (May 19, 2020); and U.S. Customs & 

Border Protection, COVID–19 Laboratory and 

Gauger Postponement Letter (May 26, 2021), 

https://www.cbp.gov/document/guidance/covid-19- 

gauger-postponement-letter. 

Research Study Section Microbiology and 

Infectious Diseases Research Study Section. 

Date: October 24–25, 2023. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bahia Resort Hotel, 998 West 

Mission Bay Drive, Ventana Room, San 

Diego, CA 92109. 

Contact Person: Eleazar Cohen, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institute of Health, 5601 

Fishers Lane, RM 3G62, Bethesda, MD 20892, 

(240) 669–5081, ecohen@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: September 19, 2023. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–20655 Filed 9–22–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Customs and Border Protection 

Accreditation and Approval of Saybolt 

LP (Guayanilla, PR) as a Commercial 

Gauger and Laboratory 

AGENCY: U.S. Customs and Border 

Protection, Department of Homeland 

Security. 

ACTION: Notice of accreditation and 

approval of Saybolt LP (Guayanilla, PR), 

as a commercial gauger and laboratory. 

SUMMARY: Notice is hereby given, 

pursuant to CBP regulations, that 

Saybolt LP (Guayanilla, PR) has been 

approved to gauge petroleum and 

certain petroleum products and 

accredited to test petroleum and certain 

petroleum products for customs 

purposes for the next four years as of 

November 16, 2020. 

DATES: Saybolt LP (Guayanilla, PR) was 

approved and accredited as a 

commercial gauger and laboratory as of 

November 16, 2020. The next inspection 

date will be scheduled for November 

2024. 

FOR FURTHER INFORMATION CONTACT: Mr. 

Robert P. Munivez, Laboratories and 

Scientific Services, U.S. Customs and 

Border Protection, 4150 Interwood 

South Parkway, Houston, TX 77032, tel. 

281–560–2937. 

SUPPLEMENTARY INFORMATION: Notice is 

hereby given pursuant to 19 CFR 151.12 

and 19 CFR 151.13, that Saybolt LP, 

Road 127, Km 11.7, Guayanilla, PR 

00656, has been approved to gauge 

petroleum and certain petroleum 

products and accredited to test 

petroleum and certain petroleum 

products for customs purposes, in 

accordance with the provisions of 19 

CFR 151.12 and 19 CFR 151.13 as of 

November 16, 2020.1

Saybolt LP (Guayanilla, PR) is 

approved for the following gauging 

procedures for petroleum and certain 

petroleum products from the American 

Petroleum Institute (API): 

API Chapters Title 

3 ................... Tank Gauging. 

7 ................... Temperature Determination. 

8 ................... Sampling. 

12 ................. Calculations. 

17 ................. Marine Measurement. 

Saybolt LP (Guayanilla, PR) is 

accredited for the following laboratory 

analysis procedures and methods for 

petroleum and certain petroleum 

products set forth by the U.S. Customs 

and Border Protection Laboratory 

Methods (CBPL) and American Society 

for Testing and Materials (ASTM): 

CBPL No. ASTM Title 

27–01 .......................................... D287 Standard Test Method for API Gravity of Crude Petroleum and Petroleum Products (Hydrometer 

Method). 

27–02 .......................................... D1298 Standard Test Method for Density, Relative Density, or API Gravity of Crude Petroleum and Liquid Petroleum Products by Hydrometer Method. 

27–08 .......................................... D86 Standard Test Method for Distillation of Petroleum Products at Atmospheric Pressure. 

27–11 .......................................... D445 Standard Test Method for Kinematic Viscosity of Transparent and Opaque Liquids (and Calculation of Dynamic Viscosity). 

27–13 .......................................... D4294 Standard Test Method for Sulfur in Petroleum and Petroleum Products by Energy-Dispersive Xray Fluorescence Spectrometry. 

27–48 .......................................... D4052 Standard Test Method for Density, Relative Density, and API Gravity of Liquids by Digital Density Meter. 

N/A .............................................. D1657 Standard Test Method for Density or Relative Density of Light Hydrocarbons by Pressure Hydrometer. 

Anyone wishing to employ this entity 

to conduct laboratory analyses and 

gauger services should request and 

receive written assurances from the 

entity that it is accredited or approved 

by the U.S. Customs and Border 

Protection to conduct the specific test or 

gauger service requested. Alternatively, 

inquiries regarding the specific test or 

gauger service this entity is accredited 

or approved to perform may be directed 

to the U.S. Customs and Border 

Protection by calling (202) 344–1060. 

The inquiry may also be sent to 

CBPGaugersLabs@cbp.dhs.gov. Please 

reference the website listed below for a 

complete listing of CBP approved 

gaugers and accredited laboratories. 

http://www.cbp.gov/about/labsscientific/commercial-gaugers-andlaboratories. 

James D. Sweet, 

Laboratory Director, Houston, Laboratories 

and Scientific Services. 

[FR Doc. 2023–20688 Filed 9–22–23; 8:45 am] 

BILLING CODE 9111–14–P 


ddrumheller on DSK120RN23PROD with NOTICES1